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Purpose: To compare the surgical outcomes of the two different methods used for Ahmed Glaucoma Valve (AGV) 
implantation between the donor scleral graft method and the partial-thickness scleral flap method.
Methods: We retrospectively reviewed medical records of 28 eyes of 26 patients diagnosed as neovascular glauco-
ma followed by AGV implantation. Based on the surgical method, the included eyes were divided into two groups. 
In the graft group (n = 18), the drainage tube was inserted into the anterior chamber, and then covered with pre-
served donor sclera. In the flap group (n = 10), the drainage tube was inserted under the partial-thickness scleral 
flap, and then covered with the flap. We compared the postoperative intraocular pressure (IOP), surgical success 
rates, and postoperative complications between the two groups.
Results: Postoperative IOP was not significantly different between the two groups (p = 0.967, 0.495 at 12 months, 
24 months, respectively, by the Mann-Whitney U-test). The mean success periods were 53.1 ± 10.1 months in 
the graft group versus 50.9 ± 9.4 months in the flap group (p = 0.882 by log rank test), and cumulative success 
rates were 77.8% and 80.0% at one year, respectively. However, tube migration occurred more frequently in the 
flap group than in the graft group (p = 0.037 by Fisher's exact test).
Conclusions: In AGV surgery for neovascular glaucoma, the scleral graft method may be associated with relatively 
less complication about tube migration than the scleral flap method. The surgical results, however, were not stat-
istically different.
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Various glaucoma drainage devices (GDDs) have been 
used for the treatment of refractory glaucomas, such as neo-
vascular glaucoma (NVG), and the performance of GDDs 
can be significantly different among each individual product 
[1-3]. There are two types of GDDs, depending on the flow 
of aqueous humor being regulated. For example, the Molteno 
implant (IOP Inc., Costa Mesa, CA, USA) and Baerveldt im-
plant (Pharmacia/UpJohn, Brdigewater, NJ, USA) do not 
regulate the flow of aqueous humor; however, the Krupin im-
plant (Hood Laboratories, St. Pembroke, MA, USA) and 
Ahmed Glaucoma Valves (New World Medical Inc, Rancho 
Cucamonga, CA, USA) regulate the flow of aqueous humor. 
Of those, the Ahmed Glaucoma Valve (AGV) is one of the 
more commonly used flow-restricted implants in refractory 
glaucomas. The valve mechanism consists of two thin sili-
cone elastomer membranes, 8 mm long and 7 mm wide, which 
allow one-way regulation of the flow with a goal of keeping 
the intraocular pressure (IOP) between 8 and 10 mmHg in the 
early postoperative period [4]. There are two surgical meth-
ods for tube coverage used in AGV implantation. In the first 
method, the drainage tube is covered with preserved donor 
sclera or Tutoplast (pericardium, dura, etc.), after it is in-
serted into the anterior chamber. The second method requires 
covering the drainage tube with an autologous scleral flap, 
after the tube is inserted into the anterior chamber under the 
partial-thickness scleral flap. Such differences may yield the 
cost-cutting and high dependence on donor sclera’s avail-
ability in the graft group, but it will not be an issue for the flap 
counterpart, which only demands a mastery of surgical skill.
To the best of our knowledge, there have been few studies 
that compared the outcomes of two different surgical techni-
ques used for AGV implantation. The purpose of this study is 
to compare the surgical outcomes between the scleral graft 




We retrospectively reviewed the medical records of pa-
tients diagnosed as NVG who underwent AGV implantation 
at the Eulji General Hospital in Seoul, Korea between 
January 2001 and December 2007. The institutional review 
board of Eulji Medical Center approved the study protocol 
before patient enrollment.
Inclusion criteria were as follows: 1) age between 20 to 85 
years, 2) inadequately controlled NVG due to proliferative 
diabetic retinopathy (PDR) or central retinal vein occlusion 
(CRVO), and 3) an IOP above 22 mmHg in spite of max-
imum tolerated medical therapy. Patients who had no light 
perception preoperatively or who underwent the AGV im-
plantation for other secondary glaucomas were excluded 
from this study.
All of the participants had follow-up periods of six months 
or longer after AGV implantation. Preoperative data in-
cluded age, sex, implanted AGV model, preoperative IOP, 
and the number of topical IOP depressants. The eyes were 
divided into two groups according to the surgical methods 
covering the silicone drainage tube of AGV. In the graft 
group (n = 18), the drainage tube was inserted into the ante-
rior chamber, and then covered with preserved donor sclera. 
In the flap group (n = 10), the drainage tube was inserted un-
der the partial-thickness scleral flap, and then covered with 
the flap. 
The selection of the surgical method for each patient de-
pended on the donor sclera’s availability when the operation 
was planned. That is, when the donor sclera was available, 
we performed the AGV surgery using the donor sclera graft 
method; otherwise we performed the surgery using the scler-
al flap method. The donor sclera used in AGV implantation 
was obtained from patients diagnosed with traumatic eyeball 
rupture at our hospital. The remaining cornea, lens, and uvea 
(iris, ciliary body, and choroid) of the enucleated eyeballs 
were clearly removed with scissors and blades. Only the 
sclera was preserved in 99.9% ethyl alcohol at a refrigerator 
temperature at 4℃. 
The donor had no abnormal results on laboratory tests for 
infectious diseases such as hepatitis, acquired immunodeficiency 
syndrome, and syphilis. All patients were operated on by one 
surgeon (JSP). The S2 model had been used before 2004, 
while the FP7 model replaced the S2 model since 2004. 
All patients underwent AGV implantation under retro-
bulbar anesthesia. A fornix-based conjunctival-Tenon’s cap-
sule flap was created in the superotemporal or superonasal 
quadrant, and blunt dissection was performed between 
Tenon’s and the episclera for AGV implantation beyond the 
equator of the globe. The tip of the drainage tube was then ir-
rigated with a 26-gauge blunt cannula containing BSS
 (Alcon 
Laboratories Inc., Fort Worth, TX, USA) for priming. The 
valved plate body was then inserted posteriorly into the 
sub-Tenon’s space and sutured to the sclera with 9-0 nylon 
sutures through the anterior positional holes of the valved 
plate body, 8 mm posterior to the limbus. The tip of the drain-
age tube was then cut and beveled up in order to extend by 2 
to 3 mm into the anterior chamber. A paracentesis was then 
made at the limbus, and a small amount of viscoelastic mate-
rial was injected into the anterior chamber. In the graft group, 
the anterior chamber was then entered through the limbal 
area, approximately 0.5 to 1 mm posterior to the limbus, us-
ing a 23-gauge needle. The drainage tube was then inserted 
into the anterior chamber parallel to the iris plane and was se-
cured to the sclera with 10-0 nylon sutures. The preserved 
donor sclera was then rehydrated in a BSS bath and trimmed 
to approximately 4 × 7 mm in size. The drainage tube was 
then covered with preserved donor sclera to avoid potential 
complications such as tube erosion, and the donor scleral 
graft was sutured to the underlying sclera at each corner with 
10-0 nylon sutures. The conjunctiva and Tenon’s capsule 
were then sutured back to the original position using 8-0 vicr-
yl sutures.
In the flap group, a half-thickness, rectangular, 4 × 4 mm 
and limbal-based scleral flap was created. The valved plate 
body was then inserted posteriorly into the sub-Tenon’s space 
and sutured to the sclera with 9-0 nylon sutures through the 
anterior positional holes of the valved plate body, 8 mm pos-
terior to the limbus. The anterior chamber was then entered 
with a 23-gauge needle under the scleral flap, then the drain-
age tube was inserted into the anterior chamber and was se-
cured to the sclera with 10-0 nylon sutures. The scleral flap 
over the drainage tube was re-attached to the sclera and su-
tured with 10-0 nylon sutures.
Complete surgical success is defined as 6 mmHg ≤ IOP ≤ 
21 mmHg without IOP-lowering medication, additional 
glaucoma surgery, nor loss of light perception during the fol-
low-up period. Qualified success is defined as 6 mmHg ≤ 
IOP ≤ 21 mmHg with supplemental medication, but without 
loss of light perception. Mean success periods are defined as 
a time to maintain “qualified success” or “complete success” 
from an initial visit, and those were compared to each other 
by log rank test. Failure is defined as follows: 1) constant hy-
potony below 6 mmHg, 2) IOP > 21 mmHg despite of sup-
plemental medication at least three times consecutively, 3) 
further glaucoma surgical intervention or recommendation 
thereof, or 4) loss of light perception. Further surgical inter-
vention for glaucoma is defined as additional glaucoma sur-
gery that requires a return to the operating room, such as 
placement of another tube shunt, tube exchange, and tube re-
moval, etc. Intracameral injection of air or viscoelastics for 
maintaining the anterior chamber was excluded from this cat-
egory and would not be recorded as evidence of failure until 
three months postoperative. 
We collected data such as IOP, and postoperative compli-
cations at one day, one week, two weeks, one month, three 
months, six months, and one year or more postoperatively 
until the last visit. IOP was measured with a Goldmann ap-HY Lee, et al. Two Methods of the AGV Surgery
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Table 1. Baseline characteristics in the graft group and flap group
   Graft group (n = 18)   Flap group (n = 10)  p -value 
 Age  61.78 ± 10.11 64.10 ± 12.83 0.683
*
 Sex  0.689
†
     Male    10 (55.6)      7 (70.0) 
     Female       8 (44.4)      3 (30.0) 
Diabetes mellitus   16 (88.9)      9 (90.0)  1.000
†
Systemic hypertension     6 (33.3)      4 (40.0)  1.000
†
Follow-up (mon)  40.5 ± 23.1  42.7 ± 25.8 0.793
* 
Preoperative IOP (mmHg)  49.9 ± 9.8 51.5 ± 12.1  0.829
* 




    NVG (DM)    17 (94.4)     8 (80.0) 
    NVG (CRVO)    1 (5.6)     2 (20.0) 
AGV model 0.265
†
    S2 14 10
    FP7 4 0
No. of prior glaucoma surgery  0 0  
Values are presented as mean ± SD or number (%).




Fig. 1. The baseline and postoperative intraocular pressure (IOP) 
measurements in the graft group and flap group. Only at six months 
postoperatively did the graft group have a significantly lower mean 
IOP compared to the flap group (indicated by an asterisk, p = 0.006 
by Mann-Whitney U-test). After that time, postoperative IOP values 
were not significantly different between the two groups (p-values by 
Mann-Whitney U-test were 0.967, 0.287, and 0.495 at 12 months, 
18 months, and 24 months, respectively). Preop = preoperative.
planation tonometer. We prescribed topical IOP-depressants 
(maximally, three eye drops) for the patients with an IOP 
more than 21 mmHg during follow-up periods. 
Statistical analysis was done by SPSS ver. 17.0 (SPSS Inc., 
Chicago, IL, USA). The preoperative data for the two groups 
were compared using the Mann-Whitney U-test or Fisher’s 
exact test. The complete success rate, qualified success rate, 
and failure rate were analyzed by Fisher’s exact test. The 
postoperative complications were compared using Pearson 
chi-square test or Fisher’s exact test. The survival curves for 
the success rates in each group were calculated using the 
Kaplan-Meier method. A p-value of less than 0.05 was con-
sidered statistically significant.
Results
This study investigated 28 eyes (18 eyes in the graft group 
and ten eyes in the flap group). Table 1 summarizes the base-
line characteristics for each group. The mean ages were 
61.78 ± 10.11 years in the graft group and 64.10 ± 12.83 
years in the flap group (p = 0.683). The preoperative mean 
IOP was 49.9 ± 9.8 mmHg in the graft group and 51.5 ± 12.1 
mmHg in the flap group (p = 0.829). The male to female ra-
tio, frequency of diabetes mellitus and systemic hyper-
tension, and preoperative numbers of topical IOP-depres-
sants were not significantly different between the two 
groups. The preoperative diagnoses in the two groups in-
cluded NVG associated with PDR in 17 eyes (94.4%) in the 
graft group versus eight eyes (80.0%) in the flap group, and 
CRVO in one eye (5.6%) in the graft group versus two eyes 
(20.0%) in the flap group. All patients had angle-closure 
stage NVG. No eyes had undergone any glaucoma surgery 
before AGV implantation.
The mean IOP values in the graft group versus the flap 
group were as follows (Fig. 1): 17.4 ± 8.5 mmHg versus 17.3 Korean J Ophthalmol Vol.25, No.5, 2011
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Table 2. The surgical results of both group at postoperative six months and one year
   Postoperative period Result Graft group (%) Flap group (%) p-value
*
   6 mon Complete success rate 22.2 (4 / 18) 10.0 (1 / 10) 0.626
Qualified success rate 72.2 (13 / 18) 80.0 (8 / 10) 0.509
Failure rate 5.6 (1 / 18) 10.0 (1 / 10) 1.000
   1 yr Complete success rate 22.2 (4 / 18) 10.0 (1 / 10) 0.626
Qualified success rate 55.6 (10 / 18) 70.0 (7 / 10) 0.689
Failure rate 22.2 (4 / 18) 20.0 (2 / 10) 1.000
*Analyzed by Fisher's exact test.
Table 3. Postoperative complications in the graft group and flap group
　 Graft group (n = 18) Flap group (n = 10) p-value
Hyphema  6 (33.3) 5 (50.0) 0.387
*
Tube erosion   1 (5.6) 3 (30.0) 0.116
†
Tube migration 0 (0.0) 3 (30.0) 0.037
†
Shallow anterior chamber  7 (38.9) 4 (40.0) 1.000
†
Tube obstruction  5 (27.8) 3 (30.0) 1.000
†
Bullous keratopathy 0 (0.0) 1 (10.0) 0.357
†
Choroidal detachment   1 (5.6) 0 (0.0) 1.000
†
Early hypotony
‡     2 (11.1) 0 (0.0) 0.524
†
Values are presented as number (%).
*Aanalyzed by Pearson chi-square test; 
†Analyzed by Fisher's exact test; 
‡Indicates hypotony occurring within the first postoperative month.
Fig. 2. The cumulative survival graph was determined by the 
Kaplan-Meier method, and the success rate was compared using the 
log rank test. The cumulative success rates were 94.4% versus 
90.0% at six months and 77.8% versus 80.0% at one year in the 
graft and flap groups, respectively. The success rates were not sig-
nificantly different (p = 0.882 by log rank test).
± 10.4 mmHg at postoperative one day (p = 0.530), 9.5 ± 3.1 
mmHg versus 14.5 ± 7.2 mmHg at postoperative one week (p 
= 0.468), 15.8 ± 5.4 mmHg versus 14.3 ± 3.6 mmHg at post-
operative two weeks (p = 0.580), 19.4 ± 5.2 mmHg versus 
18.8 ± 7.4 mmHg at postoperative one month (p = 0.501), 
and 18.8 ± 5.5 mmHg versus 17.7 ± 6.6 mmHg at postoperative 
three months (p = 0.486). However, the stastically significant 
(p = 0.006) mean IOP at six months postoperatively was 16.4 ± 
5.4 mmHg in the graft group and 27.4 ± 10.5 mmHg in the 
flap group. No other significant differences were observed (p 
= 0.967, 0.287, and 0.495 at 12 months, 18 months, and 24 
months, respectively by Mann-Whitney U-test). Moreover, 
there was no significant difference between the two groups in 
the mean number of postoperative topical IOP-depressants.
Six months postoperative, complete and qualified success 
rates were 22.2% (4 / 18) and 72.2% (13 / 18) in the graft group, 
and 10.0% (1 / 10) and 80.0% (8 / 10) in the flap group, respectively. 
At postoperative one year, the complete and qualified suc-
cess rates were 22.2% (4 / 18) and 55.6% (10 / 18) in the graft 
group, and 10.0% (1 / 10) and 70.0% (7 / 10) in the flap group, 
respectively (Table 2). However, none of these were sig-
nificantly different. On the other hand, the cumulative suc-
cess rates were 94.4% versus 90.0% at six months and 77.8% 
versus 80.0% at one year in the graft and flap groups, re-
spectively (Fig. 2). The mean success periods were 53.1 ± 
10.1 months in the graft group and 50.9 ± 9.4 months in the 
flap group (p = 0.882 by log rank test).  
Table 3 summarizes postoperative complications for each 
group. We defined tube erosion as  as  as the exposure of the tube 
through conjunctival thinning or dehiscence, and tube migra-
tion as a dislocation of the tube posteriorly out of the anterior 
chamber or anteriorly contacting the corneal endothelium. HY Lee, et al. Two Methods of the AGV Surgery
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Postoperative complications in the graft group included shal-
low anterior chamber in seven eyes (38.9%), hyphema in six 
eyes (33.3%), tube obstruction in five eyes (27.8%), early hy-
potony in two eyes (11.1%), tube erosion in one eye (5.6%), 
choroidal detachment in one eye (5.6%), and tube migration 
in no eye (0.0%). In the flap group, there were hyphema in 
five eyes (50.0%), shallow anterior chamber in four eyes 
(40.0%), tube erosion in three eyes (30.0%), tube migration 
in three eyes (30.0%), tube obstruction in three eyes (30.0%), 
and bullous keratopathy in one eye (10.0%). The frequency 
of tube migration was significantly higher in the flap group 
(p = 0.037). Despite being not statistically significant, the 
flap group had a higher frequency of tube erosion than the 
graft group (p = 0.116). A case of the tube erosion in the graft 
group underwent an additional patch graft of the preserved 
donor sclera. In the flap group, outward migration of the tube 
in addition to tube erosion occurred in two eyes. In these cas-
es, we repositioned the tube and securing it again to the 
sclera. In one case in the flap group, the inward migration of 
the tube and severe tube erosion occurred, due to the dis-
location of the valved plate body. Several trials to repair the 
exposure site with preserved donor sclera were made, but 
failed due to graft melting and further migration of the tube 
with tube-corneal touch, which caused the eye to develop 
bullous keratopathy. 
Discussion
The aim of the present study was to compare the surgical 
outcomes of the two methods for AGV implantation. In our 
study, the graft group and flap group did not show significant 
differences in terms of postoperative IOP and the mean suc-
cess period. At about six months postoperative, we observed 
three cases of tube obstruction and subsequent temporary el-
evation of IOP in the flap group. Such factors as a small sam-
ple size (n = 10) and an abrupt change of individual IOP 
might have affected the overall mean IOP, and thereby re-
sulted in significant deviation from the normal. The overall 
success rate of AGV implantation varies among different 
types of glaucoma, ranging from 63% to 100% at one year of 
follow-up [5-9]. The one-year cumulative success rate 
(77.8% and 80.0%, respectively) after AGV implantation in 
this study was similar to that from previous studies.
All cases, which had shallow anterior chamber or early hy-
potony in the graft group, were spontaneously resolved in the 
postoperative one week. Two eyes, which had persistent 
shallow anterior chamber or hypotony in the flap group, were 
treated with intracameral injection of viscoelastics or air. We 
observed no tube migration in the graft group, but three eyes 
(30.0%) demonstrated tube migration in the flap group, 
which was statistically significant (p = 0.037). Due to the dif-
ferences in the two surgical methods by nature, in the flap 
group, the tube penetrates half thickness of sclera, but in graft 
group, the tube penetrates the full thickness of sclera. As a re-
sult, the length of penetrance by the tube was shorter in the 
flap group. Consequently, the scleral support for the drainage 
tube can be weaker in the flap group than in the graft group, 
and is more likely to migrate from the original location. 
Furthermore, the scleral flap covering the drainage tube was 
thinner (half-thickness) and smaller (4 × 4 mm) in the flap 
group than the donor scleral graft (4 × 7 mm) in the graft 
group. As a result, we postulate that tube migration could be 
highly observable in the flap group relative to the graft group. 
In addition, in the flap group, making a partial-thickness 
scleral flap takes more time, requiring precise technique. 
Therefore, the surgeon’s skill could affect the surgical com-
plications more under the flap group.
However, we need to consider the potential problems 
when a preserved donor sclera is used for covering the drain-
age tube. Donor scleral grafts may transmit several infectious 
diseases. Seiff et al. [10] reported evidence of the human im-
munodeficiency virus (HIV) genome in sclera obtained from 
HIV-1 seropositive donors, despite treatment with heat, alco-
hol, or formalin. By contrast, there is no potential infectious 
disease transmission when the drainage tube is covered with 
an autologous scleral flap. Graft patch materials such as do-
nor sclera and Tutoplast can also cause immune-mediated 
melting and tube erosion. According to Raviv et al. [11], no 
eyes had tube erosion when pericardial patch grafts were 
used in 44 eyes for 10.2 months, but graft thinning was noted 
in 5 of 44 cases. Smith et al. [12] followed up 64 glaucoma-
tous eyes for at least 24 months after GDDs implantation us-
ing the Molteno implant, Baeveldt implant, or Krupin 
implant. They divided eyes into three groups according to 
graft material, (donor sclera, dura, or pericardium), and 
looked for signs of graft thinning and tube erosion. Their 
study shows that donor patch graft thinning occurred in 6 of 
23 donor sclera eyes (26.1%), 4 of 18 donor dura eyes 
(22.2%), and 6 of 23 donor pericardium eyes (26.1%), none 
of which were statistically significant. 
Although we used preserved donor sclera for covering the 
drainage tube, we were also able to use Tutoplast to cover the 
drainage tube. Tutoplast is more readily available and easier 
to handle because of its uniform quality and size. In addition, 
Tutoplast has been sterilized through gamma-irradiation and 
chemical treatment [13-15], but it is more expensive than do-
nor sclera.
 We concluded that the frequency of tube migration was 
significantly higher in the flap group than the graft group. 
However, postoperative IOP values and surgical success 
rates were not significantly different between the two 
methods. This study has some limitation due to the lack of 
long-term follow-up and small case number. Further studies 
with longer follow-up and larger case number will be needed 
to assure our conclusion.
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